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The availability of biotherapeutic products to patients has a major impact on the success in treating many
life-threatening and chronic diseases. These products are often derived by recombinant DNA technology
and are expensive for the majority of patients who need them most. Increasing numbers of patents/data
protection are now expiring and biologicals “similar” to the originators (innovative products) are coming
to the market. This process is seen as a mechanism for increasing the access to biotherapeutic products
which are very much needed for the treatment of chronic diseases worldwide. The emergence of Similar
Biological Products (SBPs) has created numerous challenges in developing, licensing, and using these
important products. From a public health perspective, the overall expectation is that similar products will
be available at an affordable price and will increase patients’ access to the therapy.
In response to the requests for assistance in deﬁning regulatory requirements for SBPs, the WHO
Expert Committee on Biological Standardization (ECBS) adopted the newWHO Guidelines for evaluation
of SBPs in October 2009. This article provides a brief account of the WHO initiative to assist its member
states to establish national requirements for the regulatory oversight of SBPs. The aim of the article is to
inform its readers of the current status of WHO Guidelines on the evaluation of similar biotherapeutic
products and of the plan to strengthen national regulatory requirements to assure quality, safety and
efﬁcacy of similar biotherapeutic products at the global level.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
As part of its mission in setting standards for biological products,
WHO provides guidelines and recommendations for manufacturing
and evaluating biologicals. The development of new standards, as
well as the revision of existing standards for assessing quality,
safety and efﬁcacy of biologicals, requires thorough scientiﬁc
review of available data and preparation of scientiﬁc evidence to
support a proposed standard. A broad consultation process with
leading experts in the area and consensus building on evolving
regulatory issues are essential elements for maintaining credibility
of the WHO standardization programme. In this context, scientiﬁc
principles outlined in recently adopted WHO Guidelines for eval-
uation of SBPs, serve as a benchmark for global acceptability oflth Organization. The author
publication and they do not
iews of the World Health
ll rights reserved. The World Healththese products. This is an area of great importance for public health
at the global level. The common problem in both developing and
developed countries is limited access to biotherapeutic products.
Innovative products beneﬁt from data protection and market
exclusivity for a certain period of time. However, the recent expi-
ration of patents and/or data protection for the ﬁrst major group of
biotherapeutics opens the door to similar products entering the
market subsequent to the innovative biotherapeutics. An increasing
number of similar biotherapeutic products (SBPs) that are under
development or are already licensed in many countries, as well as
the fact that the world biotech market is growing fast, clearly show
the importance of making these products available. Success in
treatingmany life-threatening and chronic diseases depends on the
availability of biotherapeutic products to patients. In general, these
products are often derived by recombinant DNA technology and are
expensive for the majority of patients who need them most. The
overall expectation is that similar products will be available at
affordable price and will increase patients' access to the therapy.
However, the emergence of SBPs has created numerous challenges
in developing, licensing, and using these important products. This
intention of this article is to inform a broad audience of theOrganization has granted the Publisher permission for the reproduction of this article.
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into regulatory and manufacturers' practice.
2. Evaluation of similar biotherapeutic products (SBPs) in the
context of WHO biological standardization
As part of its mandate to assure the quality of biological products
used for prevention and treatment of diseases, the World Health
Organization (WHO) undertakes a number of activities to assist its
member states. One of these is focused on the development of
WHO international standards for the quality, safety and efﬁcacy
parameters used in the evaluation of biologicals. A range of prod-
ucts that support regulation of biologicals worldwide have been
developed by the WHO to assist national regulatory authorities
(NRAs) and manufacturers to achieve this goal. Through its bio-
logical standardization program, WHO provides international
written and physical standards that underpin the assessment of
biologicals and provide a basis for deﬁning the acceptance criteria
for licensing these products worldwide. Written standards are
deﬁned by the WHO Expert Committee on Biological Standardiza-
tion (ECBS) both for product classes and individual products and
are published in theWHO Technical Report Series (TRS) in the form
of recommendations and guidelines for production, quality control
and evaluation of biologicals. They are available to the users, free of
charge, and can be found at the WHO biologicals web site (http://
www.who.int/biologicals/en/). A complete list of available phys-
ical standards, called International Biological Reference Prepara-
tions, can be obtained from the above mentioned WHO biologicals
web site (see also article by Thorpe and Wadhwa, this volume).
The two main categories of international standards include:
2.1. Written standards that deﬁne quality, safety and efﬁcacy
speciﬁcations for biological products
WHO recommendations and guidelines for production, quality
control and evaluation of biologicals are scientiﬁc and advisory in
nature. Speciﬁcations regarding quality, safety and efﬁcacy and
principles for the non-clinical and clinical evaluation of biologicals
described in these documents form the basis for the establishment
of national regulatory requirements for these products. Further-
more, these documents serve as a benchmark for global accept-
ability of these products and for prequaliﬁcation of vaccines for the
UnitedNations (UN) supply. Therearemanydocuments that provide
guidance on the issues that are common for all vaccines (i.e.,
stability, non-clinical and clinical evaluation) as well as those that
apply to a particular type of vaccine (e.g., oral polio vaccine (OPV),
inactivated Polio vaccine (IPV), rotavirus and pneumococcal conju-
gate vaccines). On the other hand, guiding principles for biologicals
are mainly provided as general principles that apply to all classes of
biologicals (i.e. vaccines, blood products and biotherapeutics). With
respect to SBPs, the ﬁrst set of guiding principles was established by
WHO as a written standard for these products in October 2009 [1].
There are several Guidances that apply to biotherapeutic products
and they have already been recognized as requiring revision and
updating in the near future [2e5]. Following their adoption by the
ECBS,WHO recommendations and guidelines become the subject of
implementation into regulatory and manufacturers’ practices.
Implementation may be conducted either directly through NRAs
and manufacturers or through Pharmacopeias.
2.2. WHO international biological reference preparations
WHO International Biological Reference Preparations (IBRP)
deﬁne the International Unit of biological activity and provide the
basis of a uniform system for reporting the results of biologicalactivity of the preparations used for the prevention or treatment of
diseases. The concept of using well-characterized preparations as
references for assessing biologicals is fundamental for ensuring the
quality of these products as well as the consistency of production.
These WHO preparations are intended for use in the calibration of
the activity of secondary preparations (regional, national or in-
house working standards) in laboratory assays. Detailed informa-
tion about WHO International Standards and Reference prepara-
tions is available at http://www.who.int/biologicals/reference_
preparations/en/. WHO Collaborating Centers for biological stan-
dardization play a pivotal role in the development of international
reference preparations. In particular, the National Institute for
Biological Standardization and Control (NIBSC), in the UK, is the
leading center for the development and distribution of interna-
tional reference preparations.
One of the critical issues in assessing similar biotherapeutic
products is the fact that the evaluation process heavily relies on the
comparability to a Reference Biotherapeutic Product (RBP). These
preparations are manufactured for the treatment of diseases and
their use in assessing SBPs is elaborated in theWHOGuidelines. It is
important to understand that WHO International Reference Bio-
logical Preparations are not intended to serve as RBPs and should
not be used for that purpose. The distinction between IBRPs and
RBPs is clear. IBRPs serve as a reference for deﬁning biological
activity in an internationally agreed unit while RBPs serve as
a comparator in demonstrating similarity of a SBP to a RBP in terms
of quality, safety and efﬁcacy parameters (see also article by Thorpe
and Wadhwa, this volume).
3. Concept of WHO guidelines on evaluation of SBPs: current
status and way forward
One of the features of these WHO Guidelines is that they
provide the principles for evaluation of SBPs and serve as a basis
for setting national requirements. At the same time, the Guide-
lines leave space for regulators to formulate additional and/or
more speciﬁc national requirements on certain issues according to
the national regulatory framework and legislation, as well as
particular circumstances.
A key prerequisite for appropriate regulation is the expertise
and experience of regulators. The application of principles provided
in the WHO Guidelines requires a good understanding of biological
regulation, and appropriate knowledge about the products that are
subject to evaluation. It also requires a certain level of knowledge
about the characteristics of these products as well as relevant
expertise and experience in assessing biotherapeutic products
through full licensing application. Therefore, technical expertise in
NRAs is of critical importance for the development of SBPs of
assured quality. Detailed guidance on clinical and statistical eval-
uation of the SBPs is also provided in the document. Although the
Guidelines cannot answer all questions regarding the clinical trial
design and the interpretation of the data generated in clinical trials,
they provide a basis for identifying key elements that should be
assessed. It is expected that the recently adopted WHO Guidelines
will be implemented into regulatory andmanufacturers’ practice in
all WHO regions but it is difﬁcult to deﬁne the timeline for that
process. In line with this, WHO has set up a plan to provide further
assistance in building technical expertise at the NRAs and NCLs.
With respect to the status of the WHO Guidelines, it is consid-
ered as a living document that needs to be further developed in line
with the knowledge and experience gained with the development,
regulation and use of SBPs. Additional WHO guidelines and
support to NRAs in the countries that are strategically important
for the global development, manufacture, regulation and use of
biotherapeutic products are envisaged. In addition to the
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national requirements were recognized as an immediate need at
the global level. One of themain driving forces in this process is the
feedback from countries where the development of SBPs is
ongoing. Regular reports on the progress in this area will be
provided to the ECBS for information and advice on the next steps.
Finally, it should be noted that guidance documents issued by
other bodies were considered in developing the WHO Guidelines.
The intention was to complement existing documents without
creating a conﬂict.
4. Evaluation of SBPs: scope, key deﬁnitions and principles
for licensing SBPs
The critical component for the evaluation of similar bio-
therapeutic products is an appropriate legislative framework for
SBPs. The importance of regulating these products according to the
requirements for biologicals is emphasized in the Guidelines. This is
based on the scientiﬁc understanding of the nature and charac-
teristics of biotherapeutic products derived by recombinant DNA
technology. Since biotherapeutic medicinal products consist of
large and highly complex protein entities that are difﬁcult to
characterize, the approach established for generic medicines is not
appropriate for the evaluation and licensing of biotherapeutics
(Fig. 1). In line with this, it is clearly stipulated in the WHO
Guidelines that biotherapeutic products should be evaluated as
biologicals, not as chemical medicinal products.
4.1. Scope
The Guidelines apply to well established and well-characterized
biotherapeutic products such as recombinant DNA-derived thera-
peutic proteins.
Vaccines and plasma-derived products and their recombinant
analogs are excluded from the scope of this document. Detailed
WHO recommendations and regulatory guidance for these products
are already available elsewhere (http://www.who.int/biologicals/
areas/en/).
4.2. Key deﬁnitions
SBP is a biotherapeutic product which is “similar” in terms of
quality, safety, and efﬁcacy to an already-licensed reference bio-
therapeutic product (RBP).Fig. 1. Applicability of licensing requirementsRBP is used as the comparator for head-to-head studies with the
SBP to show similarity in terms of quality, safety, and efﬁcacy. Only
an originator product that was licensed on the basis of a full
licensing dossier can serve as an RBP. It is important to understand
that RBPs do not refer to measurement standards such as interna-
tional, pharmacopeial or national standards or reference
preparations.
Comparability exercise is a head-to-head comparison of a bio-
therapeutic product with a licensed originator product, the RBP, with
the goal to establish similarity in quality, safety and efﬁcacy. Products
should be compared in the same study using the same procedures.
4.3. Key principles
The demonstration of similarity of an SBP to a licensed bio-
therapeutic product for which there is substantial evidence of
safety and efﬁcacy is one of the key principles in establishing an
SBP. This should be done through full comparability exercises
starting with the comprehensive assessment of the quality char-
acteristics of the SBP and RBP. This is a prerequisite for the reduc-
tion of non-clinical and clinical data required for licensure. A
stepwise approach is recommended. Evaluation of the data after
each step of the comparability exercise should serve as a basis for
decision regarding the further development of a product.
Another important issue is to recognize that the intention to
develop a similar biotherapeutic product may not result in SBP. If
major differences are found in the quality, non-clinical, and clin-
ical studies, the product should not be considered as “similar,”
and therefore other options for its further development should
be considered (e.g., submission of a full dossier for licensing). It is
important to note that biotherapeutics which are not shown to
be similar to a RBP should not be described as “similar,” nor
called an “SBP.” Failure in proving similarity does not mean that
the product may not be suitable for use but indicates that the
product cannot be licensed on the basis of the knowledge gained
on the originator product used as RBP and should not be referred
to as an SBP.
The choice of an RBP is a central issue in the comparability
exercise and has broad implications for the use of SBP. The RBP
should be licensed based on full quality, safety, and efﬁcacy data.
Therefore, an SBP should not be considered as a choice of RBP for
the time being.
Regarding the terminology for SBPs, it is one of the NRA respon-
sibilities to deﬁne the term to be used in that particular jurisdiction.to different types of medicinal products.
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appropriate term. However, it is expected that the deﬁnition of the
termwill correspond to the evaluationpathway. Details regarding the
data required and the procedure for licensing SBPs, the choice of RBP,
and other relevant details should be provided in the national
requirements. Therefore, national requirements may become more
speciﬁc and more precisely deﬁned than WHO Guidelines. Slight
differences among national regulatory requirements may be accept-
able, and not unexpected due to national circumstances, providing
that the application of the globally agreed principles, outlined in
WHO Guidelines, is appropriate.
5. Implementation of WHO guidelines on evaluation of SBPs
into practice: challenges and constraints
The WHO Guidelines established in 2009 [1], could be adopted
fully or partially by NRAs worldwide for updating their national
requirements or used as a basis for establishing their own regula-
tory system. These Guidelines provide globally acceptable princi-
ples for evaluating SBPs for licensing these products worldwide.
However, this is the ﬁrst step toward the provision of global advice
on the regulation of similar biotherapeutics, and it is recognized
that the document will not itself resolve all issues. One of the
responsibilities that regulators have is to implement WHO Guide-
lines into the practice. Similarly, manufacturers of biological
products play a leading role in implementing WHO recommenda-
tions into their practice. In this context, continuous and productive
communication between regulators andmanufacturers is of critical
importance for assuring the quality and safety of biologicals.
Furthermore, the involvement of various stakeholders is essential
for setting an efﬁcient mechanism for development, regulation and
use of SBPs at the national level. For example, in some countries, the
decision making process regarding the use of these products is at
the national level while in the others it takes place at the provincialFig. 2. Situation with the establishment of Regulation andlevel. Consequently, the process for setting or updating national
frameworks for these products will differ in terms of the steps that
need to be taken but also in terms of the timelines.
Theevaluationof SBPs is oneof the challenges that regulators and
developers of these products are facing. One of WHO’s roles is to
provide technical assistance and to facilitate the implementation of
Guidelines on the evaluation of SBPs into regulatory and manufac-
turers’ practice. This is a complex task that requires the establish-
ment of a functional networkof regulators,manufacturers and other
experts and important parties in this area. A series of global, regional
andnationalworkshopsareplanned totake this issue forwardand to
help in building expertise for evaluation of these products. In this
context,WHOCollaboratingCenterswithexpertise in theevaluation
of biotherapeutic products will play an important role in supporting
the NRAs and NCLs in countries where the need for technical assis-
tance and trainingwas identiﬁed. In linewith this, the development
of training materials and other tools to facilitate further develop-
ment and appropriate regulation of biotherapeutic products is
planned. Collaboration with the leading Pharmacopeias in the area
of biotherapeutics is also planned as a critical step in standardizing
biotherapeutics in general, and SBPs in particular.
According to the reports received from 13 NRAs, the number of
countries that have deﬁned legislation and regulatory require-
ments for SBPs is increasing. In July 2009, four countries (Canada,
Japan, S. Korea and Malaysia), in addition to the EU, reported that
they were prepared for licensing SBPs. In August 2010, progress in
deﬁning regulatory requirements was reported by NRAs in Brazil,
Cuba, Singapore, Iran and Jordan (Fig. 2). However, the status of
regulation and guidelines in these countries differ. Some countries
(EU, Canada, Japan, Korea, Malaysia and Singapore) have deﬁned
the regulation for SBPs and provided Guidelines for the manufac-
turers and other relevant stakeholders. In Cuba, regulatory
requirements were deﬁned and the Guidelines are being prepared.
Four countries (Brazil, Iran, Jordan and Mexico) have deﬁned theGuidelines in selected countries e status August 2010.
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these products in 2010. In Thailand, regulatory requirements and
the Guidelines are under development. Two countries with a great
potential for developing biotherapeutics (India and China) did not
prepare Guidelines for SBPs. It seems that the current regulation of
biologicals in these countries applies to SBPs. However, regulatory
requirements, as well as related terminology need to be clearly
deﬁned. In total, ten countries in addition to EU (Canada, Japan,
Korea, Malaysia, Singapore, Cuba, Brazil, Iran, Jordan and Mexico)
seem to be prepared for regulating SBPs. The information from
many countries, including USA, is missing. This does not mean that
these countries do not have regulations in place but that the reports
from them have not been provided to WHO. With respect to the
situation in USA, it was clear that a recently signed bill (March
2010) represents a major step forward in setting the legislation for
SBPs in that country. The legislation would give US FDA the
authority to approve similar biological products but manufacturers
of originators would be given a twelve year data exclusivity period.
This is not expected to change the world picture dramatically but is
expected to contribute to further development of SBPs on a long
term basis.
One of the constraints in this area, identiﬁed at the global level,
is pharmacovigilance. A key prerequisite for successful monitoring
of the clinical safety is to have an appropriate pharmacovigilance
system in place at the time of marketing authorization. Close
monitoring of the clinical safety is of critical importance for
understanding the ﬁeld performance of SBPs. It was proposed
to focus on (rare) serious adverse events (AEs) for all approved
indications. One of the key elements is the manufacturer’sFig. 3. Approved SBPs e Globalpharmacovigilance plan that should describe planned activities and
methods based on the safety speciﬁcation. It is expected that the
NRA will monitor compliance with the marketing commitments.
An important issue for monitoring SBPs is prescribing information
and label. Clear indication of the brand name, manufacturer’s name
and lot number are critical for traceability of these products and
NRAs should deﬁne national requirements for that purpose. Where
an INN is deﬁned, this should also be included. Risk minimization
measures are recognized as a mechanism that may enhance safe
use of SBPs. Evaluation of post marketing reports, including
frequency and causality of adverse events needs to be conducted in
a scientiﬁc manner.
Information regarding already approved SBPs in August 2010
(Fig. 3) showed that fourteen biosimilars had received marketing
authorization in the EU; these included somatropins, epoetins and
ﬁlgrastim products. Three countries (Canada, Japan and Singapore)
in addition to EU approved Omnitrope as an SBP in 2009. Another
SBP approved in the EU is Epoetin alfa BS “JCR” that also received
marketing authorization in Japan in 2010.
In comparison with “copy” products that are being developed,
the number of currently licensed SBPs is modest. This may be an
indicator that the biosimilar approach is too demanding for the
majority of countries and may not be selected as the pathway best
suited to their circumstances and needs for better access to bio-
therapeutic products. It is important, however, that countries
clearly distinguish the pathways used for authorization of products
and only those which strictly meet the full comparability exercise
should be called SBPs. Therefore, close monitoring of progress in
this area and timely exchange of the information is one of thepicture as of August 2010.
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more, NRAs and NCLs should make every effort to establish
a system for making the information on the assessment of SBPs
publicly available. This requires a good balance between
competing interest for information sharing and conﬁdentiality
agreements. The greatest lessons are learned from failures and,
therefore, assessments with a negative opinion are valuable
learning tools for regulators and manufacturers. In the years to
come, a number of uncertainties that biosimilars community is
facing may become clear but progress depends of the efforts and
cooperation of all involved.
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